advanced myeloproliferative neoplasms

0:05:59

How Will Advanced Technologies Enhance Myeloproliferative Neoplasm Care?

0:20:46

Biology and therapy of advanced systemic mastocytosis

0:24:52

Combination Therapy with JAK2 inhibitors in MPN

0:20:50

Prognosis and outcome of patients with advanced ET and PV

0:01:22

Recognizing PV That Has Become Advanced: Lindsey Lyle, MS, PA-C

0:02:43

The management of advanced phase MPNs

0:02:47

Dr Watts on the Investigation of INCB057643 in Advanced Myelofibrosis and MPN

0:02:53

AlloSCT in advanced systemic mastocytosis: who, when, and how?

0:04:00

Explaining Myeloproliferative Neoplasm Disease Progression to Patients

0:23:28

#BenchToBedside: Myeloproliferative Neoplasms

0:02:15

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

1:25:59

NCCN Patient Webinar: Myeloproliferative Neoplasms (MPN)

0:04:12

How MPN Researchers Collaborate to Advance Patient Care

0:02:18

Dr. Claire Harrison on the Benefits of Ruxolitinib in Advanced Myelofibrosis

0:19:03

Assessment of novel treatment options for patients with PV

0:03:09

Are there Non-Pharmacologic Strategies for Managing Myeloproliferative Neoplasms?

0:02:21

Avapritinib updates in advanced systemic mastocytosis: EXPLORER and PIONEER

0:27:27

Biology and therapy of advanced mastocytosis

0:55:17

Living with a Myeloproliferative Neoplasm - Webinar

0:05:59

Is Technology Accelerating Progress in Myeloproliferative Neoplasm Care?

0:02:51

Empowering Patients With Advanced Polycythemia Vera (PV) Through Personalized Care

0:01:06

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

0:03:23

FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the field

0:04:08

Prof Claire Harrison at ASH 2014 Highlights on myeloproliferative neoplasms